2022
A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G
Weinzimer S, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M, Bergenstal R, Phillip M, Criego A, Bergenstal R, Carlson A, Martens T, Beasley S, Johnson M, Whipple D, Hyatt J, Punel A, Grieme A, Thomas L, LaFrance A, Hasledalen C, Laffel L, Isganaitis E, Freiner E, Ambler-Osborn L, Desrochers H, Turcotte C, Naik N, Roethke L, Fisher M, Nimri R, Nevo M, Bello R, Hamou A, Hermon O, Horesh O, Shiovitch Mantzuri G, Drotz I, Yehiel N, Naveh R, Schatz D, Haller M, Albanese-O'Neill A, Sheehan E, Leey J, Smith M, Jacobsen L, Adams J, Hosford J, Whyte L, Battelino T, Dovč K, Bratina N, Šmigoc Schweiger D, Sever U, Gianini A, Murn Berkopec B, Mali B, Weinzimer S, Weyman K, Carria L, Zgorski M, Danne T, Biester T, von dem Berge T, Weiskorn J, Kordonouri O, Biester S, Aschemeier B, Remus K, Pisarek N, Sibayan J, Beck R, Mouse T, Davis J, Bailey R, Hellmann A, Reese N, Calhoun P, Strayer H, Cohen N, Henderson R, Kollman C, Kennedy J, Woodall W, Mahr I, Hood K, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C, Eggerman T. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology & Therapeutics 2022, 24: 573-582. PMID: 35363054, PMCID: PMC9353997, DOI: 10.1089/dia.2021.0568.Peer-Reviewed Original ResearchConceptsHybrid closed-loop systemGlucose levelsGlycemic controlGlycemic excursionsAdvanced hybrid closed-loop systemG armPostprandial glycemic excursionsPostprandial glycemic controlType 1 diabetesPostprandial glucose controlPrandial insulin deliveryTreatment armsCrossover trialGlucose controlMedtronic MiniMedSecondary analysisMeal sizeOvernight improvementInsulin deliveryHyperglycemiaOutcomesArmLevel 2HypoglycemiaPremeal
2021
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial
Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, Group F. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. The Lancet 2021, 397: 208-219. PMID: 33453783, PMCID: PMC9194961, DOI: 10.1016/s0140-6736(20)32514-9.Peer-Reviewed Original ResearchConceptsAdvanced hybrid closed-loop systemType 1 diabetesHybrid closed-loop systemMiniMed 670G systemGlucose levelsCrossover trialYoung adultsMultiple daily insulin injectionsSevere hypoglycaemic eventsDaily insulin injectionsComputer-generated sequencePermuted block designContinuous glucose monitoringBaseline HbACoprimary outcomesEndocrinology practiceHypoglycaemic eventsWashout periodHemoglobin levelsKidney diseaseMean ageInsulin injectionsProportion of timeContinuous glucose monitorImpaired awareness
2018
Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care 2018, 41: dc171682. PMID: 29444895, PMCID: PMC6463622, DOI: 10.2337/dc17-1682.Peer-Reviewed Original ResearchConceptsMiniMed 670G systemHybrid closed-loop therapyTotal daily insulin doseYoung adult participantsDaily insulin doseType 1 diabetesOptimal clinical useAdult participantsClosed-loop therapyHybrid closed-loop systemPivotal trialsYounger patientsInsulin doseInsulin ratioClinical guidancePercentage of timeHCL useClinical sitesClinical useMonthsStudy phaseTrialsUse ratesParticipantsDelivery patterns
2017
International Consensus on Use of Continuous Glucose Monitoring
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.Peer-Reviewed Original ResearchStandardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, Kowalski AJ, Madden P, McAuliffe-Fogarty AH, McElwee-Malloy M, Peters A, Raman S, Reifschneider K, Rubin K, Weinzimer SA. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017, 40: 1622-1630. PMID: 29162582, PMCID: PMC5864122, DOI: 10.2337/dc17-1624.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesType 1 diabetesAmerican Diabetes AssociationPediatric Endocrine SocietyDiabetic ketoacidosisEndocrine SocietyClinical EndocrinologistsPriority outcomesDiabetes AssociationT1D ExchangeHarry B. Helmsley Charitable TrustDiabetes educatorsLong-term clinical impactType 1American AssociationType 2 diabetesSteering CommitteeLeona M.Helmsley Charitable TrustMeaningful outcome measuresType 1 diabetes outcomesAdvisory Committee
2016
Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes
Saggar M, Tsalikian E, Mauras N, Mazaika P, White NH, Weinzimer S, Buckingham B, Hershey T, Reiss AL. Compensatory Hyperconnectivity in Developing Brains of Young Children With Type 1 Diabetes. Diabetes 2016, 66: 754-762. PMID: 27702833, PMCID: PMC5319714, DOI: 10.2337/db16-0414.Peer-Reviewed Original ResearchConceptsControl subjectsIntrinsic connectivityAge-matched control subjectsYoung childrenBrain intrinsic connectivityResting-state functional MRI dataType 1 diabetesSeed-based analysisCognitive functioningBlood glucoseSustained dysregulationOverall group differencesLarge multisite studyT1DYounger ageFunctional MRI dataCognitive deficitsType 1Cognitive functionObserved positive associationDiabetesMultisite studyCompensatory roleGroup differencesBrainAutomated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdultsMitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation period
2015
Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes
Mazaika PK, Weinzimer SA, Mauras N, Buckingham B, White NH, Tsalikian E, Hershey T, Cato A, Aye T, Fox L, Wilson DM, Tansey MJ, Tamborlane W, Peng D, Raman M, Marzelli M, Reiss AL. Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes 2015, 65: 476-485. PMID: 26512024, PMCID: PMC4747456, DOI: 10.2337/db15-1242.Peer-Reviewed Original ResearchConceptsEarly-onset type 1 diabetesType 1 diabetesBlood glucose levelsWhite matter volumeGlucose levelsMatter volumeTime pointsBrain volumeAge-matched control subjectsCortical gray matter volumeMeasures of hyperglycemiaMean HbA1c levelCurrent treatment guidelinesManagement of diabetesRapid brain maturationGray matter volumeTime of scanCortical surface areaHbA1c levelsTreatment guidelinesControl subjectsGlycemic variationsLongitudinal time pointsBrain maturationDiabetes
2014
Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia
Mauras N, Mazaika P, Buckingham B, Weinzimer S, White NH, Tsalikian E, Hershey T, Cato A, Cheng P, Kollman C, Beck RW, Ruedy K, Aye T, Fox L, Arbelaez AM, Wilson D, Tansey M, Tamborlane W, Peng D, Marzelli M, Winer KK, Reiss AL. Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia. Diabetes 2014, 64: 1770-1779. PMID: 25488901, PMCID: PMC4407847, DOI: 10.2337/db14-1445.Peer-Reviewed Original ResearchConceptsWhite matter growthControl subjectsAge-matched control subjectsType 1 diabetesHigh-resolution structural MRIWhite matter areasWhite matter volumeYoung childrenContinuous glucose monitoringGray matter regionsNondiabetic childrenChronic hyperglycemiaExecutive function scoresFunction scoresGlucose variabilityMatter volumeChildren ages 4Comprehensive neurocognitive testsBrain regionsLongitudinal assessmentType 1Structural MRIHyperglycemiaDiabetesMatter regions
2009
Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Bode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.Peer-Reviewed Original Research